DURATION OF ACTIVITY
April 4, 2022 through April 3, 2024
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedicusCME and Comprehensive Psychiatric Resources, Inc. MedicusCME is accredited by the ACCME to provide continuing medical education for physicians.
MedicusCME designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This 3-module course, presented by Dr. James Greenblatt, introduces a functional medicine model for AN treatment and recovery, in which the concept of AN as the result of a complex and biologically-mediated interplay between environmental, psychosocial, and metabolic factors is explored. Research supporting associations between metabolic abnormalities, dyslipidemia, micronutrient imbalances, and systemic inflammation will be objectively reviewed, illuminating critical treatment targets for today’s functional psychiatry practice and providing an empirically validated blueprint for personalized interventions. Upon completion, students will be able to substantiate the clinical utility of a functional medicine approach for AN, and safely incorporate evidence-based treatment strategies into existing therapeutic models to maximize patient outcomes.
- Describe the interaction of genetics and environmental factors as they interact to establish individual AN susceptibility / risk
- Illustrate the cycle of pathologic fear conditioning and its relevance to AN etiology / symptom persistence
- Identify common psychiatric comorbidities of AN
HOW TO CLAIM CREDIT
In order to receive AMA PRA Category 1 credit™, participants must do the following:
Read the learning objectives and faculty disclosures
Participate in the activity, review course content and learning strategies, resources and support materials provided
Complete the post-test and activity evaluation
- Achieve a score of 80% or higher on the post-test
Mariela Podolski, MD
Adult/Child and Adolescent Psychiatry
West Hartford, Connecticut
Walden Behavioral Care
Director of Child and Adolescent Psychiatry
Eating Disorder Consultant
Department of Corrections, Connecticut
Eating Disorder Consultant
DHMAS/Connecticut Valley Hospital, Connecticut
James Greenblatt, MD
Chief Medical Officer and Vice President of Medical Services
Walden Behavioral Care, Waltham, Massachusetts
Assistant Clinical Professor of Psychiatry
Tufts University School of Medicine
DISCLOSURE OF FINANCIAL RELATIONSHIPS
MedicusCME requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to MedicusCME policy.
The faculty reported the following relevant financial relationships with Accreditation Council for Continuing Medical Education (ACCME)-defined ineligible entities related to the educational content of this CE activity.
James Greenblatt, MD has disclosed financial relationships with Fullscripts for an affiliate relationship and with Atrium Health/Pure Encapsulations and Jaymac Pharmaceuticals for participating on their Speakers Boards.
Any relevant financial relationships listed for planners or content contributors have been mitigated according to MedicusCME policies. MedicusCME planners and managers have no relevant financial relationships with ineligible companies to disclose.
This activity is not supported by funds from an ACCME-defined ineligible company.
HIPPA COMPLIANCE ATTESTATION
In accordance with the Health Insurance Portability and Accountability Act (HIPAA), this educational activity, especially when utilizing patient cases for learning demonstration, will not include individually identifiable health information.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.